Barclays
CYTK icon

Barclays’s Cytokinetics CYTK Stock Holding History

Barclays’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-83,800
Closed -$5.52M – 5409
2026
Q1 		$5.52M Buy
83,800
+48,800
+139% +$3.1M ﹤0.01% 1758
2025
Q4 		$2.22M Buy
+35,000
New +$2.18M ﹤0.01% 2861
2025
Q3 		– Sell
-200
Closed -$6.61K – 5534
2025
Q2 		$6.61K Buy
+200
New +$6.96K ﹤0.01% 4951
2024
Q4 		– Sell
-10,000
Closed -$528K – 5313
2024
Q3 		$528K Buy
+10,000
New +$557K ﹤0.01% 3744
2024
Q2 		– Sell
-188,200
Closed -$13.2M – 4955
2024
Q1 		$13.2M Buy
+188,200
New +$14.6M ﹤0.01% 1217

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CYTK Position: Q2 2026 in Review

Barclays reduced its Cytokinetics (CYTK) stake by 11% in Q2 2026, selling an estimated $612K and leaving 70,642 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Barclays first reported a position in CYTK in Q3 2013 and has held it in 52 quarters since. The position peaked at $53.4M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Barclays held 70,642 shares of Cytokinetics worth $6.02M as of Q2 2026.
  • Barclays sold 8,517 Cytokinetics shares in Q2 2026, an estimated $612K.
  • Cytokinetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1743 holding.
  • Barclays first reported a position in Cytokinetics in Q3 2013 and has held it in 52 quarters since.
  • Barclays's Cytokinetics position peaked at $53.4M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.